SG11201900153XA - Androgen receptor antisense oligonucleotides - Google Patents

Androgen receptor antisense oligonucleotides

Info

Publication number
SG11201900153XA
SG11201900153XA SG11201900153XA SG11201900153XA SG11201900153XA SG 11201900153X A SG11201900153X A SG 11201900153XA SG 11201900153X A SG11201900153X A SG 11201900153XA SG 11201900153X A SG11201900153X A SG 11201900153XA SG 11201900153X A SG11201900153X A SG 11201900153XA
Authority
SG
Singapore
Prior art keywords
gyeonggi
international
giheung
gil
aso
Prior art date
Application number
SG11201900153XA
Other languages
English (en)
Inventor
Shin Chung
Daram Jung
Bongjun Cho
Kangwon Jang
Heungsik Yoon
Original Assignee
Olipass Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olipass Corp filed Critical Olipass Corp
Publication of SG11201900153XA publication Critical patent/SG11201900153XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
SG11201900153XA 2016-08-08 2017-05-24 Androgen receptor antisense oligonucleotides SG11201900153XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662372035P 2016-08-08 2016-08-08
PCT/IB2017/000697 WO2018029517A1 (en) 2016-08-08 2017-05-24 Androgen receptor antisense oligonucleotides

Publications (1)

Publication Number Publication Date
SG11201900153XA true SG11201900153XA (en) 2019-02-27

Family

ID=61161927

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900153XA SG11201900153XA (en) 2016-08-08 2017-05-24 Androgen receptor antisense oligonucleotides

Country Status (13)

Country Link
US (1) US20190345202A1 (pt)
EP (1) EP3497114A4 (pt)
JP (1) JP7407592B2 (pt)
KR (1) KR102427575B1 (pt)
CN (1) CN110072879B (pt)
AR (1) AR109303A1 (pt)
AU (1) AU2017309347B2 (pt)
BR (1) BR112019002387A2 (pt)
CA (1) CA3032549A1 (pt)
RU (1) RU2753966C2 (pt)
SG (1) SG11201900153XA (pt)
TW (1) TWI775764B (pt)
WO (1) WO2018029517A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7305542B2 (ja) * 2016-12-30 2023-07-10 オリパス コーポレーション ペプチド核酸誘導体によるエクソンスキッピング
MX2019007903A (es) * 2017-01-06 2020-07-14 Olipass Corp Oligonucleotidos antisentido de proteina asociada a sinaptosoma de 25 kda (snap25).
JP7241019B2 (ja) 2017-01-24 2023-03-16 オリパス コーポレーション Ｓｃｎ９ａアンチセンス鎮痛剤
TWI832851B (zh) * 2018-05-18 2024-02-21 韓商奧利通公司 基質金屬蛋白酶-1之反義寡核苷酸
KR102304280B1 (ko) * 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011764A1 (en) * 1991-12-12 1993-06-24 Scios Nova Inc. Fluorenyl derivatives and their use as anti-inflammatory agents
JPH08506961A (ja) * 1993-02-19 1996-07-30 ジンタ・インコーポレイテッド アンチセンスオリゴマー類を使用するアンドロゲン関連禿頭症の治療
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US6617422B1 (en) * 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
AU4494399A (en) * 1998-06-30 2000-01-24 University Of British Columbia, The Inhibitors of androgen-independent activation of androgen receptor
US20030207804A1 (en) * 2001-05-25 2003-11-06 Muthiah Manoharan Modified peptide nucleic acids
WO2005027833A2 (en) * 2003-09-12 2005-03-31 Avi Biopharma, Inc. Compound and method for treating androgen-independent prostate cancer
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
UA100253C2 (uk) * 2007-11-26 2012-12-10 Сантаріс Фарма А/С Lna-антагоністи андрогенного рецептора
KR20090098710A (ko) 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
ES2907254T3 (es) * 2012-10-11 2022-04-22 Ionis Pharmaceuticals Inc Un compuesto antisentido modificado para su uso en el tratamiento de la enfermedad de Kennedy
WO2018012261A1 (ja) * 2016-07-14 2018-01-18 株式会社日立製作所 電気品収容用筐体及びその製作方法
JP7305542B2 (ja) * 2016-12-30 2023-07-10 オリパス コーポレーション ペプチド核酸誘導体によるエクソンスキッピング

Also Published As

Publication number Publication date
KR102427575B1 (ko) 2022-08-01
KR20190055066A (ko) 2019-05-22
RU2753966C2 (ru) 2021-08-24
RU2019105298A (ru) 2020-09-11
TWI775764B (zh) 2022-09-01
WO2018029517A1 (en) 2018-02-15
AR109303A1 (es) 2018-11-21
US20190345202A1 (en) 2019-11-14
AU2017309347B2 (en) 2020-11-19
BR112019002387A2 (pt) 2019-06-04
TW201812009A (zh) 2018-04-01
JP2019527720A (ja) 2019-10-03
AU2017309347A1 (en) 2019-02-07
CN110072879A (zh) 2019-07-30
CA3032549A1 (en) 2018-02-15
JP7407592B2 (ja) 2024-01-04
RU2019105298A3 (pt) 2020-10-08
EP3497114A1 (en) 2019-06-19
CN110072879B (zh) 2023-03-10
EP3497114A4 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
SG11201900153XA (en) Androgen receptor antisense oligonucleotides
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201811457QA (en) Methods and devices for valve clip excision
SG11201803674WA (en) Systems and devices for setting an anchor
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201407200TA (en) Liquid formulation
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201804936UA (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201807138XA (en) Medical ice slurry production and delivery systems and methods
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201901271VA (en) Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
SG11201805381TA (en) Electroporation device with detachable needle array with lock-out system
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201804965SA (en) Augmented acid alpha-glucosidase for the treatment of pompe disease